

Rev03
 Update: Aug,08,2025
DATASHEET

IL-7 R alpha&TSLPR, His, Human

Cat. No.: Z05513

Product Introduction

Species	Human
Protein Construction	<div style="display: flex; justify-content: space-between; align-items: center;"> <div style="background-color: #0056b3; color: white; padding: 5px; text-align: center;"> IL-7 R alpha&TSLPR (Glu21-Asp239 (IL-7 R alpha) and Gln23-Lys231 (TSLPR)) Accession # P16871-1(IL-7 R alpha)&O9HC73-1(TSLPR) </div> <div style="background-color: #92d050; color: white; padding: 5px; text-align: center;">His</div> </div> <div style="display: flex; justify-content: space-between; font-size: small; margin-top: 5px;"> N-term C-term </div>
Purity	> 95% as determined by BisTris PAGE
Endotoxin Level	Less than 1EU per µg by the LAL method.
Biological Activity	Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System	HEK293
Theoretical Molecular Weight	31.18 kDa (IL-7 R alpha) and 29.03 kDa (TSLPR)
Apparent Molecular Weight	Due to glycosylation, the protein migrates to 58-68 kDa (IL-7 R alpha) and 50-58 kDa (TSLPR) based on Bis-Tris PAGE result.
Formulation	Supplied as 0.22 µm filtered solution in PBS (pH 7.4).
Concentration	Verified by one or more methods from A280/Bioactivity/BCA/Bradford.
Storage & Stability	This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles.

Background

Target Background : IL-7R alpha & TSLPR is a heterodimeric receptor, with TSLP as the ligand, which initiates downstream signaling pathways upon binding to TSLP and subsequently participates in thymus development and immune cell generation. Among them, IL-7R alpha is a component of both the IL-7 and TSLP receptors.

Synonyms : IL7Ra; CD127; TSLP R; CRLF2; IL-XR; ILXR; p2RY8; TSLPR; CRL2; CRLF2Y

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China